Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

Journal article


Morgan, Celia J. A., Page, Emma, Schaefer, Carola, Chatten, Katharine, Manocha, Amod, Gulati, Sumit, Curran, H. Valerie, Brandner, Brigitta and Leweke, F. Markus 2013. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. British Journal of Psychiatry. 202 (5), pp. 381 - 382. https://doi.org/10.1192/bjp.bp.112.121178
AuthorsMorgan, Celia J. A., Page, Emma, Schaefer, Carola, Chatten, Katharine, Manocha, Amod, Gulati, Sumit, Curran, H. Valerie, Brandner, Brigitta and Leweke, F. Markus
Abstract

Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ9-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.

Year2013
JournalBritish Journal of Psychiatry
Journal citation202 (5), pp. 381 - 382
PublisherRoyal College of Psychiatrists
ISSN0007-1250
Digital Object Identifier (DOI)https://doi.org/10.1192/bjp.bp.112.121178
Scopus EID2-s2.0-84877598259
Page range381 - 382
Research GroupSchool of Philosophy
Place of publicationUnited Kingdom
Permalink -

https://acuresearchbank.acu.edu.au/item/8qx37/cerebrospinal-fluid-anandamide-levels-cannabis-use-and-psychotic-like-symptoms

Restricted files

Publisher's version

  • 0
    total views
  • 0
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as